Passage Bio
IPO News: Filed S-1/A: Passage Bio Launches 7.4mm Share IPO with $16-$18 Marketing Range
Passage Bio

Passage Bio

Nasdaq:  PASG

Initial Public Filing Date:  02/03/20

Launch Date:  02/18/20

Price Range:  $16.00 - $18.00

Shares Offered (Pre-Shoe | mm):  7.4

Primary Shares (mm):  7.4

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $125.8

% Secondary:  0.0%

Shares Outstanding (mm):  39.4

Market Value at Midpoint (mm):  $669.8

Offering as % of Market Value:  18.8%

Bookrunners:  J.P. Morgan | Goldman Sachs | Cowen

Co-Manager:  Chardan

Major Holders:  OrbiMed | Versant Ventures | Frazier Life Sciences | LAV Prescience Limited | New Leaf Ventures | Vivo Capital | James Wilson (Scientific Founder) | AI Passage

Description:  Passage Bio is a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system, or CNS, disorders with limited or no approved treatment options.

Note:  Emerging Growth Company


Reference Link:  S-1/A